| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly earnings of $0.00 per share which missed the analyst consensus estimate...
UBS analyst Ashwani Verma downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Buy to Neutral and maintains the price target...
Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across va...
Leerink Partners analyst Marc Goodman downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Outperform to Market Perform and ...
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Buy to Neutral and l...
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...